Published 15 years ago, Chris Lipinski's landmark paper on the 'rule of five' guidelines for predicting the likelihood that drug candidates would be orally bioavailable (Adv. Drug Deliv. Rev. 23, 3–25; 1997) catalysed the emergence of approaches to improve the quality of chemicals in screening libraries, and has since been cited more than 4,000 times. Speaking with Peter Kirkpatrick, he discusses the impact of such approaches as well as efforts to expand drug-like chemical space and drug repositioning initiatives, which he has advised on at Melior Discovery since he retired from his position as senior research fellow at Pfizer in 2002.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Chris Lipinski. Nat Rev Drug Discov 11, 900–901 (2012). https://doi.org/10.1038/nrd3895
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3895
